LB Pharmaceuticals Announces Positive Topline Results from Phase 2 Trial of LB-102 in Schizophrenia Robust 359 patient trial met primary endpoint with statistically significant reduction in PANSS total score at all dose levels compared to placebo Clinically meaningful effect sizes were...

UPDATE – LB Pharmaceuticals Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference NEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapies for the treatment of neuropsychiatric diseases, including...

LB Pharmaceuticals Announces Presentation at the 43rd Annual J.P. Mogan Healthcare Conference NEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapies for the treatment of neuropsychiatric diseases, including...

LB Pharmaceuticals Names Heather Turner as CEO to Lead its Development of Transformative Advances in Schizophrenia Treatment Turner, a seasoned biotechnology executive, was formerly CEO of Carmot Therapeutics, which was acquired by Roche in 2024 for $2.7 billion LB Pharma’s lead asset, LB-102, is a patent protected...